Loading
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Latest filing published 06 Aug 2026 for Acrivon Therapeutics, Inc., €1,557. Read the official filing
Filing timeline
BuySaleAdam D. Levy
Insider track record
Disclosed buys
1
Disclosed sells
1
T+90 hit rate
0%
T+90 mean return
-6.8%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Adam D. Levy: trading record in brief
Adam D. Levy discloses dealings in Acrivon Therapeutics, Inc. to SEC (Form 4). Over a trading history stretching from 1 August 2025 to 4 August 2026, the count stands at 3 filings.
Both buying and selling appear: 1 purchase worth €13k, against 1 sale worth €1,557. On balance, insiders were net buyers of €11k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 1 share grant. So far in 2026, the count stands at 1 purchase and 1 sale.
On 6 August 2026 came the latest disclosure, an open-market sale for €1,557 in Acrivon Therapeutics, Inc. The clock since the last published purchase (16 January 2026) now reads 275 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Adam D. Levy
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
1,142 shares@ US$1.57Common StockSEC:0000905148-26-003499:0
8,832 shares@ US$1.698390.9% of flowCommon StockSEC:0000905148-26-000225:0
Canonical exit: 14 Apr 2026 (T+90)
1,164 shares@ US$1.26100.0% of flowCommon StockSEC:0000905148-25-002732:0
3 of 3 declarations
